Vista Pharma surges by 10 per cent on acquiring ANDA for UROCARE

Nikita Singh
/ Categories: Trending, Markets

The share price of Vista Pharmaceuticals surged by about 10 per cent on the bourses in intraday trade on Tuesday as the company announced that it has signed a non-disclosure agreement (NDA) for acquiring a complex ANDA for UROCARE.

 

The specified ANDA will be manufactured at a USFDA approved contract manufacturing unit of the company for a period of two years, according to a company release. The following brand has a market size of Rs. 8,840 crore in the US, according to IMS data.

 

In Tuesday’s trade, the stock hit an intraday high of Rs. 36.90 per share and an intraday low of Rs. 33 per share on BSE. The stock had touched its 52-week high of Rs. 56.15 per share on March 1, 2018 and its 52-week low of Rs. 25.70 per share on August 16, 2017 on BSE, respectively.

 

At 15:16 hours IST, the stock was trading at Rs. 36.90 per share, up by 9.99 per cent on BSE on Tuesday. Meanwhile, S&P BSE Sensex was trading at 35,035.29 level, down by 0.37 per cent and NSE Nifty50 was trading at 10,656.15 level, down by 0.30 per cent.

Previous Article Uflex posts 12 per cent hike in revenue in Q4FY18
Next Article Weak global cues may see markets making a negative start
Rate this article:
2.5

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR